RecruitingNot ApplicableNCT05810402

Liver Cancer and Immunotherapy in the Liquid Biopsy Era

Liver Cancer and Immunotherapy : Clinical Relevance of LIquid BioPSY

Sponsor

University Hospital, Montpellier

Enrollment

60 participants

Start Date

Jun 28, 2023

Study Type

INTERVENTIONAL

Conditions

Hepatocellular Carcinoma Immune Checkpoint Inhibitor Liquid Biopsy BCLC Stage C Hepatocellular Carcinoma BCLC Stage B Hepatocellular Carcinoma

Summary

The goal of this prospective clinical trial is to identify a predictive biomarker in patients with advanced HCC (stage B and C) using a combinatorial approach of the liquid biopsy. The main questions it aims to answer are: * Is multi-omic liquid biopsy approach able to identify a strong predictive biomarker of immunotherapy efficiency? * Is there a correlation between tissue biopsy (PD-L1 tissue level of expression) and liquid biopsy (detection of CTC expressing PD-L1) in HCC patients? Participants blood will be collected at several time points.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is monitoring people with advanced liver cancer who are being treated with immunotherapy (PD-1 or PD-L1 inhibitors) and looking at liquid biopsy — blood tests that detect cancer DNA — to track how the cancer responds to treatment over time. **You may be eligible if...** - You are 18 or older - You have advanced hepatocellular carcinoma (liver cancer) at Barcelona Clinic Liver Cancer stage B or C - Your doctors recommend immunotherapy as your first-line treatment - You have not yet received any prior systemic (whole-body) cancer treatment **You may NOT be eligible if...** - You have already had systemic treatment for liver cancer - Your liver cancer is at an early or very early stage - You are not a candidate for immune checkpoint therapy Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALLiquid Biopsy

30mL blood sample: * 1 x 10mL CellSave tube specifically designed for the collection and preservation of CTCs for CellSearch® analysis * 1 EDTA tube for PBMCs isolation and circulating immune cells study (5mL), * 2 EDTA tubes and 1 dry tube (15mL) for the preparation of the biobank (serum, plasma and cell).

Locations(1)

CHU Montpellier

Montpellier, France

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05810402

Related Trials

Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular Carcinoma

NCT044727671 location

Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma

NCT069022461 location

SBRT Plus Systemic Therapy vs Systemic Therapy Alone in BCLC C Hepatocellular Carcinoma

NCT072747741 location

Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors

NCT070589483 locations

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

NCT065031461 location